Positron Emission Tomography (PET) Imaging of Paediatric Patients with High-Risk Neuroblastoma Using 64Cu-SARTATE: A Multi-Centre, Open-Label, Non-Randomised, Phase-1 Imaging Investigation.

Trial Profile

Positron Emission Tomography (PET) Imaging of Paediatric Patients with High-Risk Neuroblastoma Using 64Cu-SARTATE: A Multi-Centre, Open-Label, Non-Randomised, Phase-1 Imaging Investigation.

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs 64Cu-MeCOSar-Octreotate (Primary)
  • Indications Neuroblastoma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Clarity Pharmaceuticals
  • Most Recent Events

    • 07 Sep 2017 New trial record
    • 15 Aug 2017 According to a Clarity Pharmaceuticals media release, this trial has been granted Ethics Approval by The Childrens Hospital at Westmead and and is planning to complete site set up by the end of August 2017, followed by trial recruitment in September 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top